Literature

  1. Abbott. Can the FreeStyle Libre system be used by children? Abbott. 2019.
    Link
  2. Abbott Freestyle Libre User Guide. 2018.
    Link
  3. Adolfsson P, Parkin CG, Thomas A, Krinelke LG. Selecting the Appropriate Continuous Glucose Monitoring System - a Practical Approach. touch ENDOCRINOLOGY 2018;14(2):24–29. 
    Link
  4. Akturk HK, Snell-Bergeon JK, Rewers A, Klaff LJ, Bode BW, Peters AL, Bailey TS, Garg SK. Improved Postprandial Glucose with Inhaled Technosphere Insulin Compared with Insulin Aspart in Patients with Type 1 Diabetes on Multiple Daily Injections: The STAT Study. Diabetes Technol Ther. 2018 Oct;20(10):639-647.
    Link
  5. Aleppo G, Laffel LM, Ahmann AJ, Hirsch IB, Kruger DF, Peters A, Weinstock RS, Harris DR. A Practical Approach to Using Trend Arrows on the Dexcom G5 CGM System for the Management of Adults With Diabetes. J Endocr Soc. 2017 Nov 20;1(12):1445-1460.
    Link
  6. Allen N, Gupta A. Current Diabetes Technology: Striving for the Artificial Pancreas. Diagnostics. 2019 Mar 15; 9(1). pii:E31.
    Link
  7. Alexopoulos AS, Blair R, Peters AL. Management of Preexisting Diabetes in Pregnancy A Review. JAMA. 2019;321(18):1811-1819.
    Link
  8. American Diabetes Association. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2020. Diabetes Care. 2020 Jan;43(Suppl.1):S98-S110.
    Link
  9. American Diabetes Association. Diabetes Technology: Standards of Medical Care in Diabetes—2019. Diabetes Care. 2019 Jan; 42(Supplement 1): S71-S80.
    Link
  10. American Diabetes Association. Glycemic Targets: Standards of Medical Care in Diabetes—2019. Diabetes Care. 2019 January.
    Link
  11. American Diabetes Association. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2019. Diabetes Care. 2019 Jan;42(Suppl 1):S90-S102.
    Link
  12. American Diabetes Association Professional Practice Committee, ElSayed N et al. Diabetes Technology: Standards of Medical Care in Diabetes-2023. Diabetes Care. 2023;46(Supplement_1):S111–S127.
    Link
  13. Argento NB. Flash Glucose Monitoring: A Patient's and Clinician's Caveats and Concerns. Endocr Pract. 2018 Oct 2;24(10):928-931.
    Link
  14. Argento NB, Nakamura K, Sala RD, Simpson P. Hemoglobin A1C, mean glucose, and persistence of glycation ratios in insulin-treated diabetes. Endocr Pract. 2014 Mar;20(3):252-60.
    Link
  15. Baily TS, Bode BW, Buckingham BA, Forlenza GP, Pinhas-Hamiel O, Kaiserman K, Liljenquist DR, Shulman DI, Wood MA, Chen X, Shin J, Cordero TL, Lee SW and Kaufman. Glycemic Outcomes from the MiniMed™ 670G System Pivotal Trials in Patients 2-75 Years of Age. American Diabetes Association. 2019 Jun.
    Link
  16. Battelino T, Conget I, Olsen B, et al. The use and efficacy of continuous glucose monitoring in type 1 diabetes treated with insulin pump therapy: a randomised controlled trial. Diabetologia. 2012;55(12):3155-3162.
    Link
  17. Beck RW, Connor CG, Mullen DM, Wesley DM, Bergenstal RM. The Fallacy of Average: How Using HbA1c Alone to Assess Glycemic Control Can Be Misleading. Diabetes Care. 2017 Aug;40(8):994-999.
    Link
  18. Beck RW, Riddlesworth T, Ruedy K, Ahmann A, Bergenstal R, Haller S, Kollman C, Kruger D, McGill JB, Polonsky W, Toschi E, Wolpert H, Price D; DIAMOND Study Group. Effect of Continuous Glucose Monitoring on Glycemic Control in Adults With Type 1 Diabetes Using Insulin Injections: The DIAMOND Randomized Clinical Trial. JAMA. 2017 Jan 24;317(4):371-378.
    Link
  19. Bergenstal RM, Beck RW, Close KL, Grunberger G, Sacks DB, Kowalski A, Brown AS, Heinemann L, Aleppo G, Ryan DB, Riddlesworth TD, Cefalu WT. Glucose Management Indicator (GMI): A New Term for Estimating A1C From Continuous Glucose Monitoring. Diabetes Care. 2018 Nov;41(11):2275-2280.
    Link
  20. Bergenstal RM, Tamborlane WV, Ahmann A, Buse JB, Dailey G, Davis SN, Joyce C, Perkins BA, Welsh JB, Willi SM, Wood MA, and for the STAR Study Group. Sensor-Augmented Pump Therapy for A1C Reduction (STAR 3) Study. Diabetes Care. 2011 Nov;34(11):2403–2405.
    Link
  21. Beyond Type 1 survey on CGM, October 2018. Dexcom and Beyond Type 1 survey on CGM: awareness, cost, mental effort still major issues in T1D.
    Link
  22. Blevins TC, Bode BW, Garg SK, et al; AACE Continuous Glucose Monitoring Task Force. Statement by the American Association of Clinical Endocrinologists Consensus Panel on Continuous Glucose Monitoring. Endocr Pract. 2010;16(5):730-745.
    Link
  23. Blevins TC. Professional continuous glucose monitoring in clinical practice 2010. J Diabetes Sci Technol. 2010;4(2):440-456.
    Link
  24. Bode BW. Advanced Hybrid Closed-Loop (AHCL) Pivotal Safety Study. The Next Generation of Automated Insulin Delivery Systems for Persons with Type 1 Diabetes-Four New Clinical Trials. Diabetes Journals. Jun 12, 2020.
    Link
  25. Bode BW, corresponding author Johnson JA, Hyveled L, Tamer SC, and Demissie M. Improved Postprandial Glycemic Control with Faster-Acting Insulin Aspart in Patients with Type 1 Diabetes Using Continuous Subcutaneous Insulin Infusion. Diabetes Technol Ther. 2017 Jan 1;19(1):25–33.
    Link
  26. Bolinder J, Antuna R, Geelhoed-Duijvestijn P, Kröger J, Weitgasser R. Novel glucose-sensing technology and hypoglycaemia in type 1 diabetes: a multicentre, non-masked, randomised controlled trial. Lancet. 2016 Nov 5;388(10057):2254-2263.
    Link
  27. Boughton CK, Hovorka R. Advances in artificial pancreas systems. Science Translational Medicine. 2019 Mar 20;11(484).
    Link
  28. Breton MD, Kanapka LG, Beck RW, et al. A Randomized Trial of Closed-Loop Control in Children with Type 1 Diabetes. N Engl J Med. 2020;383:836-45.
    Link
  29. Brown G. Companion Medical inpen. BeyondType1. 2018 Feb 22.
    Link
  30. Brown SA, Kovatchev BP, Raghinaru D, et al. Six-Month Randomized, Multicenter Trial of Closed-Loop Control in Type 1 Diabetes. N Engl J Med. 2019; 381:1707-1717.
    Link
  31. Bruttomesso D, Laviola L, Avogaro A, Bonora E, Del Prato S, Frontoni S, Orsi E, Rabbone I, Sesti G, Purrello F; of the Italian Diabetes Society (SID). The use of real time continuous glucose monitoring or flash glucose monitoring in the management of diabetes: A consensus view of Italian diabetes experts using the Delphi method. Nutr Metab Cardiovasc Dis. 2019 May;29(5):421-431.
    Link
  32. Carlson AL; Huyett LM; Jantz J; Chang A; Vienneau T; Ly TT. Patient-Reported Outcomes for 2,335 Adults with Type 2 Diabetes Using the Omnipod Insulin Management System Show Glycemic Improvement over First 90 Days of Use. ADA 80th Scientific Sessions. 2020 Jun.
    Link
  33. Centers for Disease Control and Prevention. National Diabetes Statistics Report, 2017. Centers for Disease Control and Prevention. 2018 Mar 6.
    Link
  34. Choudhary P, Ramasamy S, Green L, et al. Real-time continuous glucose monitoring significantly reduces severe hypoglycemia in hypoglycemia-unaware patients with type 1 diabetes. Diabetes Care. 2013;36(12):4160-4162.
    Link
  35. Christiansen M, Bailey T, Watkins E, et al. A new-generation continuous glucose monitoring system: improved accuracy and reliability compared with a previous-generation system. Diabetes Technol Ther. 2013;15(10):881-888.
    Link
  36. ClinicalTrials.gov. FreeStyle LIbre Flash Glucose Monitoring System Pediatric Accuracy Study. ClinicalTrials.gov. 2019 Jan 29/June 14.
    Link
  37. Close K, Brown A. CGM and Time-in-Range: What Do Diabetes Experts Think About Goals? diaTribe. 2017 Dec 20.
    Link
  38. Conway RB et al. Racial Disparities in Diabetes Technology Adoption and Their Association with HbA1c and Diabetic Ketoacidosis. Diabetes Metab Syndr Obes. 2023 Aug;16: 2295–2310.
    Link
  39. Cobry EC, Berget C, Messer LH, Forlenza GP. Review of the Omnipod ® 5 Automated Glucose Control System Powered by Horizon™ for the treatment of Type 1 diabetes. Ther Deliv. 2020 Aug;11(8):507-519.
    Link
  40. Cobry E, McFann K, Messer L, Gage V, VanderWel B, Horton L, Chase HP. Timing of meal insulin boluses to achieve optimal postprandial glycemic control in patients with type 1 diabetes. Diabetes Technol Ther. 2010 Mar;12(3):173-7.
    Link
  41. Criego AB, Carlson AL, Forlenza GP, Bode BW, Levy CJ, Hansen DW, Hirsch IB, Brown SA, Bergenstal RM, Sherr J, Mehta SN, Laffel LM, Shah V, Bhargava A, Weinstock RS, MacLeish SA, DeSalvo D, Jones TC, Aleppo G, Buckingham BA, Ly TT, OMNIPOD 5 RESEARCH GROUP, Minneapolis, MN, Atlanta, GA, New York, NY, Seattle, WA, Charlottesville, VA, New Haven, CT, Boston, MA, Aurora, CO, West Des Moines, IA, Syracuse, NY, Cleveland, OH, Houston, TX, Macon, GA, Chicago, IL, Stanford, CA, Acton, MA. Glycemic Outcomes over 15 Months with the Omnipod 5 Automated Insulin Delivery System. ADA 82nd Scientific Sessions. 2022 Jun.
    Link
  42. Danne T, Cariou B, Buse JB, Garg SK, Rosenstock J, Banks P, Kushner JA, McGuire DK, Peters AL, Sawhney S, Strumph P. Improved Time in Range and Glycemic Variability With Sotagliflozin in Combination With Insulin in Adults With Type 1 Diabetes: A Pooled Analysis of 24-Week Continuous Glucose Monitoring Data From the inTandem Program. Diabetes Care. 2019 May;42(5):919-930.
    Link
  43. Dagogo-Jack S. Preventing diabetes-related morbidity and mortality in the primary care setting. J Natl Med Assoc. 2002;94(7):549-605.
    Link
  44. Damiano ER, McKeon K, El-Khatib FH, Zheng H, Nathan DM, Russell SJ. A comparative effectiveness analysis of three continuous glucose monitors: the Navigator, G4 Platinum, and Enlite. J Diabetes Sci Technol. 2014;8(4):699-708.
    Link
  45. Deiss D, Bolinder J, Riveline JP, et al. Improved glycemic control in poorly controlled patients with type 1 diabetes using real-time continuous glucose monitoring. Diabetes Care. 2006;29(12):2730-2732.
    Link
  46. Dexcom G6 CGM User Guide, 2018.
    Link
  47. diaTribe. Automated Insulin Delivery (Artificial Pancreas, Closed Loop). diaTribe. 2018 May 31.
    Link
  48. Edelman SV, Argento NB, Pettus J and Hirsch IB. Clinical Implications of Real-time and Intermittently Scanned Continuous Glucose Monitoring. Diabetes Care. 2018 Nov;41(11):2265-2274.
    Link
  49. El-Khatib FH, Balliro C, Hillard MA, et al. Home use of bihormonal bionic pancreas versus insulin pump therapy in adults with type 1 diabetes: a multicentre randomized cross trial. Lancet. 2017 Jan 28;389(10067):369-380.
    Link
  50. El-Khatib FH, Russell SJ, Magyar KL, et al. Autonomous and continuous adaptation of a bihormonal bionic pancreas in adults and adolescents with type 1 diabetes. J Clin Endocrinol Metab. 2014;99(5):1701-1711.
    Link
  51. El-Khatib FH, Russell SJ, Nathan DM, Sutherlin RG, Damiano ER. A bihormonal closed-loop artificial pancreas for type 1 diabetes. Sci Transl Med. 2010;2(27):27ra27.
    Link
  52. Eng DS, Lee JM. The promise and peril of mobile health applications for diabetes and endocrinology. Pediatr Diabetes. 2013;14(4):231-238.
    Link
  53. Everett C, Thorpe C, Palta M, Carayon P, Bartels C, Smith MA. Physician assistants and nurse practitioners perform effective roles on teams caring for Medicare patients with diabetes. Health Aff (Millwood). 2013;32(11):1942-1948.
    Link
  54. Everett CM, Thorpe CT, Palta M, Carayon P, Gilchrist VJ, Smith MA. The roles of primary care PAs and NPs caring for older adults with diabetes. JAAPA. 2014;27(4):45-49.
    Link
  55. FDA. The Artificial Pancreas Device System. FDA. 2018 Aug 30.
    Link
  56. FDA. What is the pancreas? What is an artificial pancreas device system? FDA. 2018 Aug 30.
    Link
  57. FDA Approves Dexcom G5® Mobile Continuous Glucose Monitoring System. First and Only Fully Mobile CGM System Allows Adults and Children as young as 2 years old to Conveniently and Discreetly Monitor and Share Glucose Levels. PRNewswire. Accessed August 25, 2015.
    Link
  58. Felman A. What are insulin pens and how do we use them? MedicalNewsToday. 2019 Mar 27.
    Link
  59. Fleming GA, Petrie JR, Bergenstal RM, Holl RW, Peters AL, Heinemann L. Diabetes Digital App Technology: Benefits, Challenges, and RecommendationsA Consensus Report by the European Association for the Study of Diabetes (EASD) and the American Diabetes Association (ADA) Diabetes Technology Working Group. Diabetes Care. 2020 01; 43(1):250-260.
    Link
  60. Fonseca VA, Grunberger G, Anhalt H, Bailey TS, Blevins T, Garg SK, Handelsman Y, Hirsch IB, Orzeck EA, Roberts VL, Tamborlane W; Consensus Conference Writing Committee. Continuous Glucose Monitoring: A Consensus Conference of the American Association Of Clinical Endocrinologists and American College of Endocrinology. Endocr Pract. 2016 Aug;22(8):1008-21.
    Link
  61. Forlenza GP, Bode BW, Carlson AL, Criego AB, Brown SA, Weinstock RS, Hansen DW, Buckingham BA, Mehta SN, Laffel LM, Sherr J, Levy CJ, Hirsch IB, Macleish SA, DeSalvo D, Shah V, Bhargava A, Jones TC, Aleppo G, Huyett LM, Ly TT, OMNIPOD 5 RESEARCH GROUP, Atlanta, GA, Minneapolis, MN, Charlottesville, VA, Syracuse, NY, Stanford, CA, Boston, MA, New Haven, CT, New York, NY, Seattle, WA, Cleveland, OH, Houston, TX, Aurora, CO, West Des Moines, IA, Macon, GA, Chicago, IL, Acton, MA. Glycemic Outcomes with the Omnipod 5 Automated Insulin Delivery (AID) System Stratified by Baseline Hypoglycemia Risk among People with Type 1 Diabetes (T1D) Ages 2 to 70 Years. ADA 82nd Scientific Sessions. 2022 Jun.
    Link
  62. Forlenza, GP. Relevance of Bolus Calculators in Current Hybrid Closed Loop Systems. Diabetes Technol Ther. 2017 Jul 1;19(7):400–401.
    Link
  63. Forlenza GP, Buckingham BA, Brown SA, Bode BW, Levy CJ. Criego AB, Wadwa RP, Cobry EC, Slover RJ, Messer LH, Berget C, McCoy S, Ekhlaspour L, Kingman RS, Voelmle MK, Boyd J, O’Malley G, Grieme A, Kivilaid K, Kleve K, Dumais B, Vienneau T, Huyett LM, Lee JB, O’Connor J, Benjamin E, Ly TT. First outpatient evaluation of a tubeless automated insulin delivery system with customizable glucose targets in children and adults with type 1 diabetes. Diabetes Technol Ther. 2020 Dec 16.
    Link
  64. Forlenza GP, Deshpande S, Ly TT, Howsmon DP, Cameron F, Baysal N, Mauritzen E, Marcal T, Towers L, Bequette BW, Huyett LM, Pinsker JE, Gondhalekar R, Doyle III FJ, Maahs DM, Buckingham BA, and Dassau E. Application of Zone Model Predictive Control Artificial Pancreas During Extended Use of Infusion Set and Sensor: A Randomized Crossover-Controlled Home-Use Trial. Diabetes Care. 2017 Aug;40(8):1096-1102.
    Link
  65. Frias JP, Gonzalez-Glavez G, Johnsson E, Maaske J, Testa MA, Simonson DC, Dronamraju N, Garcia-Sanchez R, Peters AL. Efficacy and safety of dual add-on therapy with dapagliflozin plus saxagliptin versus glimepiride in patients with poorly controlled type 2 diabetes on a stable dose of metformin: Results from a 52-week, randomized, active-controlled trial. Diabetes Obes Metab. 2020 Jul; 22(7):1083-1093.
    Link
  66. Garg SK, Editor-in-Chief. Diabetes Technology & Therapeutics, volume 21, issue 1. 2019 Jan.
    Link
  67. Garg S, Zisser H, Schwartz S, Bailey T, Kaplan R, Ellis S, Jovanovic L. Improvement in glycemic excursions with a transcutaneous, real-time continuous glucose sensor: a randomized controlled trial. Diabetes Care. 2006 Jan;29(1):44-50.
    Link
  68. Garg SK, Rodbard D, Hrisch IB, Forlenza GP. Managing New-Onset Type 1 Diabetes During the COVID-19 Pandemic: Challenges and Opportunities. Diabetes Technol Ther. 2020 Jun;22(6):431-439.
    Link
  69. Garg SK, Voelmle MK, Beatson CR, et al. Use of continuous glucose monitoring in subjects with type 1 diabetes on multiple daily injections versus continuous subcutaneous insulin infusion therapy: a prospective 6-month study. Diabetes Care. 2011;34(3):574-579.
    Link
  70. Glycemic Targets: Standards of Medical Care in Diabetes—2019. Diabetes Care. 2019 Jan; 42(Supplement 1): S61-S70.
    Link
  71. Grunberger G, Abelseth JM, Bailey TS, Bode BW, Handelsman Y, Hellman R, Jovanovič L, Lane WS, Raskin P, Tamborlane WV, Rothermel C. Consensus Statement by the American Association of Clinical Endocrinologists/American College of Endocrinology insulin pump management task force. Endocr Pract. 2014 May;20(5):463-89.
    Link
  72. Grunberger G, Bailey T, Camacho PM, et al; Glucose Monitoring Consensus Conference Writing Committee. Proceedings From the American Association of Clinical Endocrinologists and American College of Endocrinology Consensus Conference on Glucose Monitoring: AACE/ACE Consensus Statement. Endocr Pract. 2015;21(5):522-533.
    Link
  73. Grunberger G, Handelsman Y, Bloomgarden ZT, Fonseca VA, Garber AJ, Haas RA, Roberts VL, Umpierrez GE. American Association of Clinical Endocrinologists and American College of Endocrinology 2018 position statement on Integration of insulin pumps and continuous glucose monitoring in patients with diabetes mellitus. Endocr Pract. 2018 Mar;24(3):302-308.
    Link
  74. Harrell RM, Orzeck EA; American Association of Clinical Endocrinologists Socioeconomics and Member Advocacy Committee. Coding guidelines for continuous glucose monitoring. Endocr Pract. 2010;16:151-154.
    Link
  75. Heinemann L, Freckmann G, Ehrmann D, Faber-Heinemann G, Guerra S, Waldenmaier D, Hermanns N. Real-time continuous glucose monitoring in adults with type 1 diabetes and impaired hypoglycaemia awareness or severe hypoglycaemia treated with multiple daily insulin injections (HypoDE): a multicentre, randomised controlled trial. Lancet. 2018 Apr 7;391(10128):1367-1377.
    Link
  76. Hirsch IB; Weinstock RS; Huyett LM; Jantz J; Chang A; Vienneau T; Ly TT. 995-P: Real-World Insulin Delivery Patterns for 1,202 Adults with Type 2 Diabetes Using the Omnipod Insulin Management System with Cloud-Based Data Management. Diabetes Journals. 2020 Jun;69(Suppl.1):-.
    Link
  77. Hirsch IB, Armstrong D, Bergenstal RM, et al. Clinical application of emerging sensor technologies in diabetes management: consensus guidelines for continuous glucose monitoring (CGM). Diabetes Technol Ther. 2008;10(4):232-244.
    Link
  78. Isganaitis E et al. Closed-Loop Insulin Therapy Improves Glycemic Control in Adolescents and Young Adults: Outcomes from the International Diabetes Closed-Loop Trial. Diabetes Technol Ther. 2022 May; 23(5):342-349.
    Link
  79. Jacquin AE, Al-khawi L, Sanchez P, Mohanty S, Tweden KS, Kaufman FR, Germantown, MD, Los Angeles, CA. Evaluation of Accuracy and Longevity of an Implantable CGM System through 365 Days. ADA 82nd Scientific Sessions. 2022 Jun.
    Link
  80. Jacquin AE, Al-khawi L, Ghosh-Dastidar S, Tweden KS, Kaufman FR, Germantown, MD, Los Angeles, CA. Effect of Calibration Frequency on Accuracy of a 180-Day Implantable CGM System. ADA 82nd Scientific Sessions. 2022 Jun.
    Link
  81. Journal of Diabetes Science and Technology. J Diabetes Sci Technol. 2018 Jan;12(1):228–229.
    Link
  82. Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group,Tamborlane WV, Beck RW, Bode BW, et al. Continuous glucose monitoring and intensive treatment of type 1 diabetes. N Engl J Med. 2008;359(14):1464-1476.
    Link
  83. Klonoff, D et al. Investigation of the Accuracy of 18 Marketed Blood Glucose Monitors. Diabetes Care. 2018 Aug; 41 (8):1681-1688.
    Link
  84. Kudva YC, Ahmann AJ, Bergenstal RM, Gavin III JR, Kruger DF, Midyett LK, Miller E and Harris DR. Approach to Using Trend Arrows in the FreeStyle Libre Flash Glucose Monitoring Systems in Adults. J Endocr Soc. 2018 Dec 1;2(12):1320–1337.
    Link
  85. Kudva YC, Carter RE, Cobelli C, Basu R, Basu A. Closed-loop artificial pancreas systems: physiological input to enhance next-generation devices. Diabetes Care. 2014;37(5):1184-1190.
    Link
  86. Layne JE; Huyett LM; Ly TT. Glycemic Control and Factors Impacting Treatment Choice in Tubeless Insulin Pump Users: A Survey of the T1D Exchange Glu Online Community. J Diabetes Sci Technol. 2019 Aug;13(6):1180-1181.
    Link
  87. Layne JE; Parkin CG; Zisser H. Efficacy of a Tubeless Patch Pump in Patients With Type 2 Diabetes Previously Treated With Multiple Daily Injections. J Diabetes Sci Technol. 2017 Jan;11(1):178-179.
    Link
  88. Lind M, Polonsky W, Hirsch IB, Heise T, Bolinder J, Dahlqvist S, Schwarz E, Ólafsdóttir AF, Frid A, Wedel H, Ahlén E, Nyström T, Hellman J. Continuous Glucose Monitoring vs Conventional Therapy for Glycemic Control in Adults With Type 1 Diabetes Treated With Multiple Daily Insulin Injections. The GOLD Randomized Clinical Trial. JAMA. 2017;317(4):379-387.
    Link
  89. Lodwig V, Kulzer B, Schnell O, Heinemann L. Current trends in continuous glucose monitoring. J Diabetes Sci Technol. 2014;8(2):390-396.
    Link
  90. Schoelwer M, Bode BW, Carlson AL, Criego AB, Forlenza GP, Weinstock RS, Hansen DW, Buckingham BA, Mehta SN, Laffel LM, Sherr J, Levy CJ, Hirsch IB, MacLeish SA, DeSalvo D, Shah V, Bhargava A, Jones TC, Aleppo G, Gurlin RE, Ly TT, OMNIPOD 5 RESEARCH GROUP, Charlottesville, VA, Atlanta, GA, Minneapolis, MN, Syracuse, NY, Stanford, CA, Boston, MA, New Haven, CT, New York, NY, Seattle, WA, Cleveland, OH, Houston, TX, Aurora, CO, West Des Moines, IA, Macon, GA, Chicago, IL, Acton, MA. Glycemic Outcomes across Total Daily Insulin Doses with the Omnipod 5 Automated Insulin Delivery System (AID) among People with Type 1 Diabetes (T1D) Ages 2 to 70 Years. ADA 82nd Scientific Sessions. 2022 Jun.
    Link
  91. Masierek M et al. The Review of Insulin Pens-Past, Present, and Look to the Future. Front Endocrinol (Lausanne). 2022 Mar; 8:13:827484.
    Link
  92. Mehta SN, Tinsley LJ, Kruger D, Bode B, Laybe JE, Huyett LM, Dryga K, Dumais B, Ly TT, Laffel LM. Improved Glycemic Control Following Transition to Tubeless Insulin Pump Therapy in Adults With Type 1 Diabetes. Clinical Diabetes. 2021 Jan; 39(1): 72-79.
    Link
  93. Messer LH, Berget C, Forlenza GP. A Clinical Guide to Advanced Diabetes Devices and Closed-Loop Systems Using the CARES Paradigm. Diabetes Technol Ther. 2019May ; 21(8).
    Link
  94. Miller KM, Foster NC, Beck RW, Bergenstal RM, DuBose SN, DiMeglio LA, Maahs DM, Tamborlane WV; T1D Exchange Clinic Network. Current state of type 1 diabetes treatment in the U.S.: updated data from the T1D Exchange clinic registry. Diabetes Care. 2015 Jun;38(6):971-8.
    Link
  95. Misso ML, Egberts KJ, Page M, O'Connor D, Shaw J. Continuous subcutaneous insulin infusion (CSII) versus multiple insulin injections for type 1 diabetes mellitus. Cochrane Database Syst Rev. 2010 Jan 20;(1):CD005103.
    Link
  96. Monnier L, Colette C, Wojtusciszyn A, Dejager S, Renard E, Molinari N, Owens DR. Toward Defining the Threshold Between Low and High Glucose Variability in Diabetes. Diabetes Care. 2017 Jul;40(7):832-838.
    Link
  97. Moser O, Riddel MC, Eckstein ML, Adolfsson P, et al. Glucose management for exercise using continuous glucose monitoring (CGM) and intermittently scanned CGM (isCGM) systems in type 1 diabetes: position statement of the European Association for the Study of Diabetes (EASD) and of the International Society for Pediatric and Adolescent Diabetes (ISPAD) endorsed by JDRF and supported by the American Diabetes Association (ADA). Diabetologia. 2020 Oct;63: 2501-2520.
    Link
  98. Mulvey A. In First-In-Human Tests, New Artificial Pancreas System Smartphone App Shows Reliable Glucose Control. JDRF. 2019 Feb 25.
    Link
  99. Nakamura K, Balo A. The accuracy and efficacy of the Dexcom G4 Platinum continuous glucose monitoring system. J Diabetes Sci Technol. 2015 Mar 23;9(5):1021-6.
    Link
  100. National Institute for Health and Care Excellence. FreeStyle Libre for glucose monitoring. National Institute for Health and Care Excellence. 2017 Jul 3.
    Link
  101. Nirantharakumar K, Mohammed N, Toulis KA, Thomas GN, Narendran P. Clinically meaningful and lasting HbA1c improvement rarely occurs after 5 years of type 1 diabetes: an argument for early, targeted and aggressive intervention following diagnosis. Diabetologia. 2018 May;61(5):1064-1070.
    Link
    102. >
  102. Peters AL. Integration of Diabetes Technology in Clinical Practice. Endocrinol Metab Clin North Am. 2020 03; 49(1):69-77.
    Link
  103. Peters AL, Ahmann AJ, Battelino T, Evert A, Hirsch IB, Murad MH, Winter WE, Wolpert H. Diabetes Technology-Continuous Subcutaneous Insulin Infusion Therapy and Continuous Glucose Monitoring in Adults: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2016 Nov;101(11):3922-3937.
    Link
  104. Peters AL. Ahmann AJ, Hirsch IB, Raymond JK. Advances in Glucose Monitoring and Automated Insulin Delivery: Supplement to Endocrine Society Clinical Practice Guidelines. J Endocr Soc. 2018 Nov 1; 2(11): 1214–1225.
    Link
  105. Peters AL, Garg SK. The Silver Lining to COVID-19: Avoiding Diabetic Ketoacidosis Admissions with Telehealth. Diabetes Technol Ther. 2020 Jun; 22(6):449-453.
    Link
  106. Peters AL, McGuire DK, Danne T, Kushner JA, Rodbard HW, Dhatariya K, Sawhney S, Banks P, Jiang W, Davies MJ, Lapuerta P. Diabetic Ketoacidosis and Related Events With Sotagliflozin Added to Insulin in Adults With Type 1 Diabetes: A Pooled Analysis of the inTandem 1 and 2 Studies. Diabetes Care 2020. 2020 Nov; 43(11): 2713-2720.
    Link
  107. Peters AL, Piletič M, Ejstrud J, Selvesen-Sykes K, Snyder J, Bowering K. Baseline nocturnal glucose change: A predictor of the treatment effect of bolus intensification in insulin‐treated type 2 diabetes. Diabetes Obes Metab. 2019 Jul;21(7):1752-1756.
    Link
  108. Petrie JR, Peters AL, Bergenstal RM, Holl RW, Fleming GA, and Heinemann L. Improving the Clinical Value and Utility of CGM Systems: Issues and Recommendations. Diabetes Care. 2017 Dec;40(12):1614-1621.
    Link
  109. Pettus J, Edelman SV. Recommendations for Using Real-Time Continuous Glucose Monitoring (rtCGM) Data for Insulin Adjustments in Type 1 Diabetes. J Diabetes Sci Technol. 2017 Jan;11(1):138-147.
    Link
  110. Peyrot M; Bailey TS; Childs BP; Reach G. Strategies for implementing effective mealtime insulin therapy in type 2 diabetes. Current Medical Research and Opinion. 2018 Mar;34(6):1153-1162.
    Link
  111. Peyrot M, Barnett AH, Meneghini LF, Schumm-Draeger PM. Insulin adherence behaviours and barriers in the multinational Global Attitudes of Patients and Physicians in Insulin Therapy study. Diabet Med. 2012 May;29(5):682-9.
    Link
  112. Pleus S, Schmid C, Link M, et al. Performance evaluation of a continuous glucose monitoring system under conditions similar to daily life. J Diabetes Sci Technol. 2013;7(4):833-841.
    Link
  113. Polsky S, Wu M, Bode BW, DuBose SN, Goland RS, Maahs DM, Foster NC, Peters AL, Levy CJ, Shah VN, Beck RW, T1D Exchange Clinic Network. Diabetes Technology Use Among Pregnant and Nonpregnant Women with T1D in the T1D Exchange. Diabetes Technol Ther. 2018 08; 20(8):517-523.
    Link
  114. Reznik Y; Cohen O; Aronson R; , Conget I; Runzis S; Castaneda J; Lee SW. Insulin pump treatment compared with multiple daily injections for treatment of type 2 diabetes (OpT2mise): a randomised open-label controlled trial. The Lancet. 2014 Oct;384(9950):P1265-1272.
    Link
  115. Riddlesworth TD, Beck RW, Gal RL, Connor CG, Bergenstal RM, Lee S, Willi SM. Optimal Sampling Duration for Continuous Glucose Monitoring to Determine Long-Term Glycemic Control. Diabetes Technol Ther. 2018 Apr;20(4):314-316.
    Link
  116. Rombopoulos G, Hatzikou M, Latsou D, Yfantopoulos J. The prevalence of hypoglycemia and its impact on the quality of life (QoL) of type 2 diabetes mellitus patients (The HYPO Study). Hormones (Athens). 2013 Oct-Dec;12(4):550-8.
    Link
  117. Russell SJ, El-Khatib FH, Nathan DM, Magyar KL, Jiang J, Damiano ER. Blood glucose control in type 1 diabetes with a bihormonal bionic endocrine pancreas. Diabetes Care. 2012;35(11):2148-2155.
    Link
  118. Selvin E, Parrinello CM, Daya N, and Bergenstal RM. Trends in Insulin Use and Diabetes Control in the U.S.: 1988–1994 and 1999–2012. Diabetes Care. 2016 Mar; 39(3):e33–e35.
    Link
  119. Shah VN, Garg SK. Standardized Hybrid Closed-Loop System Reporting. Diabetes Technol Ther. Published Online:25 Nov 2020.
    Link
  120. Smart CE, Evans M, O'Connell SM, McElduff P, Lopez PE, Jones TW, Davis EA, King BR. Both dietary protein and fat increase postprandial glucose excursions in children with type 1 diabetes, and the effect is additive. Diabetes Care. 2013 Dec;36(12):3897-902.
    Link
  121. Šoupal J, Petruželková L, Flekač M, Pelcl T, Matoulek M, Daňková M, Škrha J, Svačina Š, Prázný M. Comparison of Different Treatment Modalities for Type 1 Diabetes, Including Sensor-Augmented Insulin Regimens, in 52 Weeks of Follow-Up: A COMISAIR Study. Diabetes Technol Ther. 2016 Sep;18(9):532-8.
    Link
  122. Stone MP, Agrawal P, Chen X, et al. Retrospective Analysis of 3-Month Real-World Glucose Data After the MiniMed 670G System Commercial Launch. Diabetes Technol Ther. 2018;20:689-92.
    Link
  123. Tamborlane WV, Beck RW, Bode BW, Buckingham B, Chase HP, Clemons R, Fiallo-Scharer R, Fox LA, Gilliam LK, Hirsch IB, Huang ES, Kollman C, Kowalski AJ, Laffel L, Lawrence JM, Lee J, Mauras N, O'Grady M, Ruedy KJ, Tansey M, Tsalikian E, Weinzimer S, Wilson DM, Wolpert H, Wysocki T, Xing D, Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. Continuous glucose monitoring and intensive treatment of type 1 diabetes. N Engl J Med. 2008 Oct 2;359(14):1464-76.
    Link
  124. Umpierrez GE, Klonoff DC. Diabetes Technology Update: Use of Insulin Pumps and Continuous Glucose Monitoring in the Hospital. Diabetes Care. 2018 Aug; 41(8): 1579-1589.
    Link
  125. van Beers CA, DeVries JH, Kleijer SJ, Smits MM, Geelhoed-Duijvestijn PH, Kramer MH, Diamant M, Snoek FJ5, Serné EH. Continuous glucose monitoring for patients with type 1 diabetes and impaired awareness of hypoglycaemia (IN CONTROL): a randomised, open-label, crossover trial. Lancet Diabetes Endocrinol. 2016 Nov;4(11):893-902.
    Link
  126. Vanstone M, Rewegan A, Brundisini F, Dejean D, Giacomini M. Patient Perspectives on Quality of Life With Uncontrolled Type 1 Diabetes Mellitus: A Systematic Review and Qualitative Meta-synthesis. Ont Health Technol Assess Ser. 2015 Sep 1;15(17):1-29.
    Link
  127. Velvadapu VN, Masciotti JM, Dehennis AD, Sanchez P, Tweden KS, Kaufman FR, Ioacara S, Germantown, MD, Los Angeles, CA, Bucharest, Romania. Evaluation of an Implantable CGM System Using a Multiple-Analyte Indicator Hydrogel for Calibration Reduction. ADA 82nd Scientific Sessions. 2022 Jun.
    Link
  128. Vigersky RA, McMahon C. The Relationship of Hemoglobin A1C to Time-in-Range in Patients with Diabetes. Diabetes Technol Ther. 2019 Feb;21(2):81-85.
    Link
  129. Vigersky RA. The benefits, limitations, and cost-effectiveness of advanced technologies in the management of patients with diabetes mellitus. J Diabetes Sci Technol. 2015;9(2):320-303.
    Link
  130. Wan W, Skandari MR, Minc A, Nathan AG, Zarei P, Winn AN, O'Grady M, Huang ES. Cost-effectiveness of Initiating an Insulin Pump in T1D Adults Using Continuous Glucose Monitoring Compared with Multiple Daily Insulin Injections: The DIAMOND Randomized Trial. Med Decis Making. 2018 Nov;38(8):942-953.
    Link
  131. Weisman A, Bai JW, Cardinez M, Kramer CK, Perkins BA. Effect of artificial pancreas systems on glycaemic control in patients with type 1 diabetes: a systematic review and meta-analysis of outpatient randomised controlled trials. Lancet Diabetes Endocrinol. 2017 Jul;5(7):501-512.
    Link
  132. Wolpert HA, Atakov-Castillo A, Smith SA, Steil GM. Dietary fat acutely increases glucose concentrations and insulin requirements in patients with type 1 diabetes: implications for carbohydrate-based bolus dose calculation and intensive diabetes management. Diabetes Care. 2013 Apr;36(4):810-6.
    Link
  133. Yaron M, Roitman Eytan, Aharon-Hananel G, Landau Z, Ganz T, Yanuv I, Rozenberg A, Karp M, Ish-Shalom M, Singer J, Wainstein J, Raz I. Effect of Flash Glucose Monitoring Technology on Glycemic Control and Treatment Satisfaction in Patients With Type 2 Diabetes. Diabetes Care. 2019 Jul; 42(7): 1178-1184.
    Link
  134. Yeh HC, Brown TT, Maruthur N, et al. Comparative effectiveness and safety of methods of insulin delivery and glucose monitoring for diabetes mellitus: a systematic review and meta-analysis. Ann Intern Med. 2012;157(5):336-347.
    Link
  135. Zaharieva D, McGaugh SM, Pooni R, Vienneau T, Ly T, Riddel M. Reducing Basal Insulin 90 Minutes before Exercise Protects Against Hypoglycemia Better than Insulin Suspension at Exercise Onset in T1D—The OmniTIME Results. Diabetes Journal. 2018 Jul; 67(1).
    Link
cgmEDUCATION.net is supported by independent educational grants from Insulet Corporation, Madrigal Pharmaceuticals, MannKind Corporation, Medtronic, and Tandem Diabetes Care, Inc.
©2024 CogniMed Inc. All rights reserved.